Global Multiple System Atrophy Patient Population Analysis and Forecast, 2026 - 2035

The report indicates that improving diagnostic accuracy through advanced neuroimaging and evolving clinical diagnostic criteria is a primary driver for the expansion of diagnosed MSA patient cohorts globally. Increased availability of specialised movement disorder centres and earlier recognition of disease-specific features are reducing misdiagnosis and enhancing epidemiological reporting reliability, leading to a larger identified patient population towards 2026.

The analysis highlights that MSA-P (Parkinsonian type) remains the most commonly diagnosed disease subtype across many geographic regions within the global patient population. Demographically, the report emphasizes the significant contribution of ageing populations, as MSA primarily affects middle-aged and older adults, which supports the gradual expansion of diagnosed patient cohorts globally.

The future patient population landscape will likely be shaped by continued improvements in diagnostic precision, including biomarker development, and broader access to specialised neurological services. These advancements are crucial for strengthening epidemiological visibility and enabling more timely diagnosis and intervention. The report suggests that patient segmentation analysis will become increasingly important as these trends evolve.

The report identifies significant symptom overlap with Parkinson’s disease as a primary challenge, which continues to delay accurate MSA diagnosis. Furthermore, limited awareness of MSA in non-specialised healthcare settings contributes to underrecognition, hindering the timely identification of affected individuals within global healthcare systems.

While not detailing specific regional numbers in this overview, the report indicates that the global patient population is influenced by varying healthcare infrastructure and diagnostic capabilities across different countries. The increasing availability of advanced neuroimaging and specialised movement disorder centres worldwide is improving diagnostic accuracy, leading to stronger epidemiological visibility across diverse global healthcare systems in both developed and emerging markets.

Improved physician education, particularly among movement disorder specialists, is directly supporting earlier diagnosis and patient referral, thereby strengthening epidemiological visibility. This increase in the identified and diagnosed patient population is crucial for understanding the true market size, which impacts strategic planning for pharmaceutical companies, diagnostic developers, and healthcare providers competing in the MSA space.